Hodgkin Lymphoma

Curated

← investigated for

Thiotepasmall_molecule

unknown

Curated

← investigated for

Pembrolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Nivolumabmonoclonal_antibody

unknown

Curated

← investigated for

Melphalansmall_molecule

unknown

Curated

← investigated for

Lomustinesmall_molecule

unknown

Curated

← investigated for

Doxorubicinsmall_molecule

unknown

Curated

← investigated for

Dacarbazinesmall_molecule

unknown

Curated

← investigated for

Cyclophosphamidesmall_molecule

unknown

Curated

← investigated for

Chlorambucilsmall_molecule

unknown

Curated

← investigated for

Carmustinesmall_molecule

unknown

Curated

← investigated for

Brentuximab Vedotinadc

unknown

Curated

← investigated for

unknown

Curated

← investigated for

Vinorelbinesmall_molecule

unknown

Curated

← investigated for

Vincristinesmall_molecule

unknown

Curated

← investigated for

Toripalimabmonoclonal_antibody

unknown

Curated

← investigated for

Tislelizumabmonoclonal_antibody

unknown

Curated

← investigated for

Sirolimussmall_molecule

unknown

Curated

← investigated for

Sintilimabmonoclonal_antibody

unknown

Curated

← investigated for

Rituximabmonoclonal_antibody

unknown

Curated

← investigated for

Procarbazinesmall_molecule

unknown

Curated

← investigated for

Prednisonesmall_molecule

unknown

Curated

← investigated for

Pegfilgrastimother

unknown

Curated

← investigated for

Panobinostatsmall_molecule

unknown

Curated

← investigated for

Methotrexatesmall_molecule

unknown

Curated

← investigated for

Ifosfamidesmall_molecule

unknown

Curated

← investigated for

Gemcitabinesmall_molecule

unknown

Curated

← investigated for

Filgrastimother

unknown

Curated

← investigated for

Etoposidesmall_molecule

unknown

Curated

← investigated for

Dexamethasonesmall_molecule

unknown

Curated

← investigated for

Cytarabinesmall_molecule

unknown

Curated

← investigated for

Cisplatinsmall_molecule

unknown

Curated

← investigated for

Carboplatinsmall_molecule

unknown

Curated

← investigated for

Camrelizumabmonoclonal_antibody

unknown

Curated

← investigated for

Bendamustinesmall_molecule

unknown

Curated

← investigated for

Vorinostatsmall_molecule

unknown

Curated

← investigated for

Treosulfansmall_molecule

unknown

Curated

← investigated for

Thioguaninesmall_molecule

unknown

Curated

← investigated for

Thalidomidesmall_molecule

unknown

Curated

← investigated for

Temsirolimussmall_molecule

unknown

Curated

← investigated for

Tanespimycinsmall_molecule

unknown

Curated

← investigated for

Sugemalimabmonoclonal_antibody

unknown

Curated

← investigated for

Ruxolitinibsmall_molecule

unknown

Curated

← investigated for

Prednisolonesmall_molecule

unknown

Curated

← investigated for

Plerixaforsmall_molecule

unknown

Curated

← investigated for

Pexidartinibsmall_molecule

unknown

Curated

← investigated for

Pacritinibsmall_molecule

unknown

Curated

← investigated for

Oxaliplatinsmall_molecule

unknown

Curated

← investigated for

Ofatumumabmonoclonal_antibody

unknown

Curated

← investigated for

Mocetinostatsmall_molecule

unknown

Curated

← investigated for

Mechlorethaminesmall_molecule

unknown

Curated

← investigated for

Leuprolideother

unknown

Curated

← investigated for

Leucovorinsmall_molecule

unknown

Curated

← investigated for

Lenalidomidesmall_molecule

unknown

Curated

← investigated for

Ipilimumabmonoclonal_antibody

unknown

Curated

← investigated for

Idelalisibsmall_molecule

unknown

Curated

← investigated for

Ibrutinibsmall_molecule

unknown

Curated

← investigated for

Goserelinother

unknown

Curated

← investigated for

Fludarabinesmall_molecule

unknown

Curated

← investigated for

Everolimussmall_molecule

unknown

Curated

← investigated for

Epirubicinsmall_molecule

unknown

Curated

← investigated for

Decitabinesmall_molecule

unknown

Curated

← investigated for

Clofarabinesmall_molecule

unknown

Curated

← investigated for

Chlormethinesmall_molecule

unknown

Curated

← investigated for

Cemiplimabmonoclonal_antibody

unknown

Curated

← investigated for

Busulfansmall_molecule

unknown

Curated

← investigated for

Bortezomibsmall_molecule

unknown

Curated

← investigated for

Bevacizumabmonoclonal_antibody

unknown

Curated

← investigated for

Azacitidinesmall_molecule

unknown

Curated

← investigated for

Avelumabmonoclonal_antibody

unknown

Curated

← investigated for

Atezolizumabmonoclonal_antibody

unknown

Curated

← investigated for

Alemtuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Aldesleukinother

unknown

Curated

← investigated for

Trastuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Romidepsinother

unknown

Curated

← investigated for

Pomalidomidesmall_molecule

unknown

Curated

← investigated for

Paclitaxelsmall_molecule

unknown

Curated

← investigated for

Obinutuzumabmonoclonal_antibody

unknown

Curated

← investigated for

Niacinamidesmall_molecule

unknown

Curated

← investigated for

Irinotecansmall_molecule

unknown

Curated

← investigated for

Dasatinibsmall_molecule

unknown

Curated

← investigated for

Daratumumabmonoclonal_antibody

unknown

Curated

← investigated for

Copanlisibsmall_molecule

unknown

Curated

← investigated for

Conatumumabmonoclonal_antibody

unknown

Curated

← investigated for

Carfilzomibother

unknown

Curated

← investigated for

Belinostatsmall_molecule

unknown

Curated

← investigated for

Abexinostatsmall_molecule

unknown

Curated

← investigated for

Tisagenlecleucelcell_therapy

unknown

0.5

Curated

Hodgkin Lymphoma altered in cohorts of …ALTERED_INderived3 of 3
← altered in cohorts of	SOCS1 38 / 61 cases (62 %) · ssm · chl_sccc_2023	—	—	Classic Hodgkin Lymphoma	1	Observed	cbioportal	graph →
← altered in cohorts of	TNFAIP3 22 / 61 cases (36 %) · ssm · chl_sccc_2023	—	—	Classic Hodgkin Lymphoma	1	Observed	cbioportal	graph →
← altered in cohorts of	B2M 20 / 61 cases (33 %) · ssm · chl_sccc_2023	—	—	Classic Hodgkin Lymphoma	1	Observed	cbioportal	graph →

Hodgkin Lymphoma altered in cohorts of …ALTERED_INderived3 of 3

← altered in cohorts of

SOCS1

38 / 61 cases (62 %) · ssm · chl_sccc_2023

—

Observed

cbioportal

← altered in cohorts of

TNFAIP3

22 / 61 cases (36 %) · ssm · chl_sccc_2023

—

Observed

cbioportal

← altered in cohorts of

B2M

20 / 61 cases (33 %) · ssm · chl_sccc_2023

—

Observed

cbioportal

Hodgkin Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 154show all (up to 200)
→ investigated in trials for	Brentuximab Vedotinadc 91 trials (27 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	91	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall_molecule 87 trials (26 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	87	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall_molecule 81 trials (18 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	81	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall_molecule 56 trials (22 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall_molecule 55 trials (15 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 54 trials (28 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 49 trials (21 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Dacarbazinesmall_molecule 48 trials (23 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Vinblastinesmall_molecule 42 trials (17 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall_molecule 39 trials (9 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal_antibody 35 trials (4 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall_molecule 34 trials (7 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Bendamustinesmall_molecule 30 trials (6 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall_molecule 25 trials (4 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Bleomycin 24 trials (7 active) · roll-up of the cancer and its descendants	—	—	Hodgkin Lymphoma	24	Observed	clinicaltrials	graph →

Hodgkin Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 154show all (up to 200)

→ investigated in trials for

Brentuximab Vedotinadc

91 trials (27 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall_molecule

87 trials (26 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall_molecule

81 trials (18 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall_molecule

56 trials (22 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall_molecule

55 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal_antibody

54 trials (28 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal_antibody

49 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dacarbazinesmall_molecule

48 trials (23 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinblastinesmall_molecule

42 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall_molecule

39 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rituximabmonoclonal_antibody

35 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall_molecule

34 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall_molecule

30 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall_molecule

25 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bleomycin

24 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

Hodgkin Lymphoma studied in …STUDIED_INderived10 of 972show all (up to 200)
→ studied in	NCT01087294Phase 1 · completed Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped CURATED_BROADER · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03560752Phase 1 · active not recruiting CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02940301Phase 2 · active not recruiting Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · condition mapped CURATED_BROADER · 972 trials mapped (220 active)	—	—	Classic Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03618550Phase 2 · recruiting Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981899Phase 1/Phase 2 · active not recruiting A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06398457early Phase 1 · recruiting Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07838649Phase 1 · not yet recruiting Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)	—	—	Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →

Hodgkin Lymphoma studied in …STUDIED_INderived10 of 972show all (up to 200)

→ studied in

NCT01087294Phase 1 · completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT01676805recruiting

Tissue Collection for Studies of Lymph Cancer · condition mapped ALIAS · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT02682667recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped ALIAS · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT03418038Phase 2 · recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped CURATED_BROADER · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT03560752Phase 1 · active not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT02940301Phase 2 · active not recruiting

Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · condition mapped CURATED_BROADER · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT03618550Phase 2 · recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT04981899Phase 1/Phase 2 · active not recruiting

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT06398457early Phase 1 · recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)

—

Observed

→ studied in

NCT07838649Phase 1 · not yet recruiting

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity · condition mapped ONTOLOGY_EXACT · 972 trials mapped (220 active)

—

Observed